---
title: "Fischer Medical Ventures Ltd (FISCHER) — Share Price, Financials & Analysis"
symbol: "FISCHER"
company: "Fischer Medical Ventures Ltd"
canonical: "https://tapetide.com/stocks/FISCHER"
isin: "INE771F01041"
nse_symbol: "FISCHER"
bse_code: "524743"
sector: "Chemicals"
industry: "Commodity Chemicals"
market_cap_cr: 2230.24
generated_at: "2026-09-13T18:59:20.538Z"
---

# Fischer Medical Ventures Ltd (FISCHER)

Canonical page: https://tapetide.com/stocks/FISCHER

## Company

- **NSE Symbol:** FISCHER
- **BSE Code:** 524743
- **ISIN:** INE771F01041
- **Sector:** Chemicals
- **Industry:** Commodity Chemicals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2005-06-08
- **CEO:** Mr. Ravindran Govindan LLB
- **Employees:** 40
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** fischermv.com

## About

Fischer Medical Ventures Ltd, earlier known as 
Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides 
AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam.[1]

## Latest Price

- **Price:** ₹35.87
- **Change:** +0.97 (+2.78%)
- **Open:** ₹35.29
- **Day High:** ₹36.14
- **Day Low:** ₹33.68
- **Previous Close:** ₹34.9
- **Volume:** 580113
- **As Of:** 2026-09-11T09:59:44+00:00

## Key Fundamentals

Observed at 2026-09-11T04:46:34.281055Z.

- **Market Cap:** ₹2230.24 Cr
- **Classification:** Microcap
- **P/E (reported):** 99.4
- **P/E (TTM):** 94.39
- **EPS (TTM):** ₹0.38
- **Book Value:** ₹6.99
- **Price to Book:** 4.98
- **Dividend Yield:** 0.14%
- **ROE:** 0.36%
- **ROCE:** 0.76%
- **Debt to Equity:** 0.28
- **Revenue (yearly):** ₹308.58 Cr
- **Net Income:** ₹29.95 Cr
- **EBITDA:** ₹43.09 Cr
- **52-Week High:** ₹124.7
- **52-Week Low:** ₹31.05
- **RSI (14):** 39.7

## Tapetide Score

- **Score:** 40 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 14.5 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 51.48 | 9% |
| growth | 98.9 | 9% |
| momentum | 31.35 | 12% |
| ownership | 65.38 | 24% |
| quality | 19.48 | 22% |
| valuation | 14.15 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Promoter holding has increased by 0.94% over last quarter.

### Weaknesses

- Stock is trading at 6.10 times its book value
- Company has a low return on equity of 5.54% over last 3 years.
- Company has high debtors of 342 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| ebitda margin growth | 523.33% | 211.6% | 22.2% |
| net income growth | 130.65% | — | 820% |
| revenue growth | -15.16% | 175.03% | — |
| roce | -390.05% | -71.21% | -84.71% |
| roe | -130.47% | -84.14% | 5.45% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 20.79 | 10.12 | 39.66 | 11.75 | 49.17 | 23.44 | 86.31 | 101.1 | 97.54 | 81.92 |
| Expenses | 0 | 18.28 | 10.33 | 39.16 | 11.38 | 46.66 | 19.45 | 70.09 | 79.53 | 101.31 | 70.67 |
| Operating Profit | 0 | 2.51 | -0.21 | 0.5 | 0.37 | 2.51 | 3.99 | 16.22 | 21.57 | -3.77 | 11.25 |
| OPM % | — | 12.07 | -2.08 | 1.26 | 3.15 | 5.1 | 17.02 | 18.79 | 21.34 | -3.87 | 13.73 |
| Other Income | 0 | 0.47 | 0.69 | 0.05 | 0.38 | 0.15 | 7.47 | 2.48 | 1.09 | 0.77 | 1.48 |
| Interest | 0 | 0.05 | 0.13 | 0.05 | 0.07 | 0.23 | 0.66 | 0.92 | 0.64 | 3.66 | 3.54 |
| Depreciation | 0 | 0.18 | 0.28 | 0.29 | 0.56 | 0.51 | 0.77 | 0.51 | 0.77 | 0.93 | 1.36 |
| Profit before tax | 0 | 2.75 | 0.07 | 0.21 | 0.12 | 1.92 | 10.03 | 17.27 | 21.25 | -7.59 | 7.83 |
| Tax % | — | 6.18 | 271.43 | -38.1 | 350 | 26.04 | 51.55 | 19.46 | 9.18 | 64.03 | 51.6 |
| Net Profit | 0 | 2.59 | -0.12 | 0.29 | -0.29 | 1.31 | 4.86 | 13.9 | 19.23 | -12.44 | 3.79 |
| EPS in Rs | 0 | 0.05 | 0 | 0.01 | -0.01 | 0.02 | 0.07 | 0.21 | 0.3 | -0.19 | 0.06 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- |
| Sales | 0 | 21 | 111 | 309 | 367 |
| Expenses | 0 | 19 | 108 | 266 | 322 |
| Operating Profit | 0 | 2 | 3 | 43 | 45 |
| OPM % | 11 | 9 | 2.6 | 14 | 12 |
| Other Income | 0 | 0 | 1 | 12 | 6 |
| Interest | 0 | 0 | 0 | 6 | 9 |
| Depreciation | 0 | 0 | 2 | 3 | 4 |
| Profit before tax | 0 | 2 | 2 | 46 | 39 |
| Tax % | — | 13 | 45 | 33 | — |
| Net Profit | 0 | 2 | 1 | 31 | 24 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.47 | 0.38 |
| Dividend Payout % | 0 | 0 | 22 | 11 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | 0 | 28 | 274 | 319 |
| Borrowings | 1 | 2 | 85 | 107 |
| Other Liabilities | 0 | 4 | 34 | 180 |
| Total Liabilities | 0 | 86 | 457 | 672 |
| Fixed Assets | 0 | 15 | 24 | 33 |
| CWIP | 0 | 0 | 1 | 3 |
| Investments | 0 | 1 | 11 | 123 |
| Other Assets | 0 | 70 | 421 | 513 |
| Total Assets | 0 | 86 | 457 | 672 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | -7 | -87 | -101 |
| Cash from Investing Activity | — | -29 | -125 | -5 |
| Cash from Financing Activity | — | 37 | 315 | 14 |
| Net Cash Flow | — | 1 | 103 | -92 |
| Free Cash Flow | — | -8 | -93 | -103 |
| CFO/OP | — | -392 | -3001 | -195 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 345 | 398 | 251 | 342 |
| Inventory Days | — | 99 | 36 | 24 |
| Days Payable | — | 48 | 82 | 191 |
| Cash Conversion Cycle | 345 | 449 | 205 | 174 |
| Working Capital Days | 324 | 498 | 40 | 155 |
| ROCE % | — | 5 | 1 | 11 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 0% | 0% | 0% | 74.91% | 74.91% | 74.91% | 62.81% | 61.8% | 61.8% | 61.8% | 62.15% | 62.15% |
| FIIs | 0% | 0% | 5.07% | 5.07% | 5.07% | 5.07% | 5.23% | 5.55% | 5.61% | 4.85% | 4.97% | 5.48% |
| DIIs | 0% | 0% | 1.68% | 1.68% | 1.68% | 1.68% | 1.44% | 1.42% | 1.42% | 1.36% | 1.38% | 1.35% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 97.6% | 97.59% | 29.37% | 16.48% | 16.39% | 16.37% | 26.52% | 26.48% | 26.23% | 26.14% | 24.91% | 24.33% |
| Others | 2.4% | 2.41% | 63.88% | 1.86% | 1.94% | 1.96% | 3.99% | 4.75% | 4.95% | 5.85% | 6.59% | 6.69% |
| No. of Shareholders | 9104 | 9038 | 8976 | 9285 | 9502 | 9688 | 10180 | 10058 | 12127 | 22920 | 23269 | 23950 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 35.96 | Sell |
| EMA (10) | 35.84 | Buy |
| SMA (20) | 36.56 | Sell |
| EMA (20) | 36.39 | Sell |
| SMA (50) | 37.6 | Sell |
| EMA (50) | 37.04 | Sell |
| SMA (100) | 36.96 | Sell |
| EMA (100) | 40.41 | Sell |
| SMA (200) | 38.7 | Sell |
| EMA (200) | 96.18 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.72 | Neutral |
| MACD (12,26,9) | -0.64 | Sell |
| Stochastic (14,3,3) | 20.49 | Neutral |
| ADX (14) | 12.86 | Neutral |
| Williams %R (14) | -54.56 | Neutral |
| ATR (14) | 1.59 | High Volatility |
| ROC (12) | -0.5 | Sell |
| Stoch RSI (14) | 54.47 | Neutral |
| UO (7,14,28) | 39.15 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6606c74e-c5d4-4409-a002-93bd8d749e2d.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b41489b-0783-4cb6-9c3b-8d015913cbab.pdf) |
| 2026-09-07 | [Intimation Of 33Rd AGM Of Fischer Medical Ventures Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8eb83bab-65a2-4a89-bdae-4ba634c06d00.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1fb3abf8-7fa7-4acd-8a2c-5e401f54754f.pdf) |
| 2026-09-07 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d8ba78f-c5ec-430a-9887-86356afabd3a.pdf) |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9e704c3-e658-41ee-b393-077ee01c9dfe.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edfc7bc0-9126-4072-9b98-7f43b4c1c28c.pdf) |
| 2026-09-03 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db05a8d7-3174-479b-88ba-e9a1fbec0966.pdf) |
| 2026-09-03 | [Record Date For E-Voting At AGM And Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a3c12fa-cb93-4efb-8836-618006633115.pdf) |
| 2026-08-28 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=490a9878-1c11-42de-8528-59f97783551a.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Financial Results For Q 1 FY 2026-27](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6da7d23-312a-4d67-85c0-056200e815f9.pdf) |
| 2026-05-31 | [Financial Results For The Quarter And Year Ended 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19225c1c-575d-460a-8f73-c37b445cddfb.pdf) |
| 2026-05-30 | [Finanacial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d980844a-5519-40e2-8e33-4b16431f4d1d.pdf) |
| 2026-01-30 | [Results- Financial Results-31/12/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3994112-8889-4395-bc94-770ea939bbf9.pdf) |
| 2025-10-28 | [Results - Financial Results 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56ddc649-d09e-49e4-a237-7bb061ff8d6d.pdf) |
| 2025-08-14 | [Results -30.06.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fe5320c-9955-4b6a-b817-ca52b805efe9.pdf) |
| 2025-08-14 | [Results-30.06.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3bd3628-28b8-4da9-bcac-ec135fe8d1df.pdf) |
| 2025-08-14 | [Results - June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7717234d-5faf-4f94-a6a3-acec3ce04bd0.pdf) |
| 2025-05-30 | [Audited Results For The Year 31.03.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46d08ea0-ac13-4f43-8497-5a4b94ceac9c.pdf) |
| 2025-05-28 | [Audited Results For The Year 31.03.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f1d6b52-f7a6-4837-ad55-e1dd3505fa1c.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Time Medical India launched CDSCO‑certified MICA and QUIN 1.5T MRI platforms at IRIA 2026, helium-free and zero boil-off. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Feb - Time Medical India launched CDSCO‑certified MICA and QUIN 1.5T MRI platforms at IRIA 2026, helium-free and zero boil-off.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/62898e51-8674-4041-b578-9b2399b33b6c.pdf) |
| 9 Apr - Regulation 74(5) certificate filed for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Regulation 74(5) certificate filed for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/313de091-5008-4028-92d2-b6c9614fb3ae.pdf) |
| 31 Mar - Promoter converted 6,000,000 warrants into shares at Rs23.40; company received Rs10.53 crore on March 31, 2026. | [Announcement under Regulation 30 (LODR)-Allotment 31 Mar - Promoter converted 6,000,000 warrants into shares at Rs23.40; company received Rs10.53 crore on March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/da056147-44b2-4de3-80ee-995c550f7988.pdf) |
| 30 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2025-26 results. | [Closure of Trading Window 30 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2025-26 results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d75a2c49-8315-470b-b51e-81984bd30f01.pdf) |
| 3 Mar - FMV Global Innovations (wholly-owned) acquired 75% of PT Fischer Pariko Medical Ventures, Indonesia (incorporated 14-10-2024). | [Announcement Under Reg 30 3 Mar - FMV Global Innovations (wholly-owned) acquired 75% of PT Fischer Pariko Medical Ventures, Indonesia (incorporated 14-10-2024).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/78be2ec9-08d8-492a-aeec-46e6f38530b4.pdf) |
| 24 Mar - Appointed Balaji Gandla as Company Secretary & Compliance Officer effective 24-Mar-2026; also secretary for wholly-owned subsidiary. | [Board Meeting Outcome for Appointment Of Company Secretary And Compliance Officer 24 Mar - Appointed Balaji Gandla as Company Secretary & Compliance Officer effective 24-Mar-2026; also secretary for wholly-owned subsidiary.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ae33bad-c444-4095-b0f6-e1a0a047b711.pdf) |
| 12 Feb - Monitoring agency: no deviation; Rs.358.46 crore preferential issue; Rs.270.40 crore raised as of Dec 31, 2025. | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report 12 Feb - Monitoring agency: no deviation; Rs.358.46 crore preferential issue; Rs.270.40 crore raised as of Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dd0df078-1c20-441c-8deb-a70945412a6d.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1 Apr](https://www.bseindia.com/xml-data/corpfiling/AttachHis/46B8A4DF_8D86_4C86_8ECD_1A25B83F0D99_151938.pdf) |
| — | [Closure of Trading Window 20 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43979714-6194-4dce-bbf9-44d3ba1d060a.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1534582-6194-4ede-bd27-31fdc14e8b7f.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2273d7c5-b5c7-4a20-bdb5-ad9d394f7b2a.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8c9b2b68-dc14-42b8-92eb-51042b4e0397.pdf) |
| Dec 2024 | [Concall - Dec 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/688bd4f9-24c8-4d8d-a121-089da90ff39d.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/42e13537-07e8-4260-9aa6-bdad9e7b9da7.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9ebf875b-3edb-4d11-91b5-b9be7a45b591.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/950076ae-2ad5-4fbb-982a-4f45351fcbcd.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/76349524743.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/71784524743.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/67635524743.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/5247430319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/5247430318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/5247430317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/524743/5247430316.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2024-12-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=688bd4f9-24c8-4d8d-a121-089da90ff39d.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:59:20.538Z.